Evidence map›Paper›PMID 40441331›Full record

SynthesisIndian heart journal

The effect of mavacamten on echocardiographic parameters, cardiac function and biomarkers in hypertrophic cardiomyopathy patients, a systematic review and meta-analysis.

Zina Otmani, Noura Abdrabou, Hazem Ayman Elsayed, Mazen Negmeldin Aly Yassin, Mohamed Abouzid, Mahmoud Diaa Hindawi, Ayman K Awad

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zina OtmaniFaculty of Medicine, Mouloud Mammeri University, Tizi Ouzou, Algeria; Medical Research Group of Egypt, Negida Academy, Arlington, MA, USA. Electronic address: otmanizina25@gmail.com.
Noura AbdrabouFaculty of Medicine, Alexandria University, Alexandria, Egypt; Medical Research Group of Egypt, Negida Academy, Arlington, MA, USA. Electronic address: nourayonis@yahoo.com.
Hazem Ayman ElsayedFaculty of Medicine, Zagazig University, Zagazig, Egypt; Medical Research Group of Egypt, Negida Academy, Arlington, MA, USA. Electronic address: hazem.azab15@gmail.com.
Mazen Negmeldin Aly YassinFaculty of Medicine, Cairo University, Cairo, Egypt; Medical Research Group of Egypt, Negida Academy, Arlington, MA, USA. Electronic address: mazen.n.yassin@gmail.com.
Mohamed AbouzidDepartment of Physical Pharmacy and Pharmacokinetics, Faculty of Pharmacy, Poznan University of Medical Sciences, Rokietnicka 3 St., 60-806, Poznan, Poland. Electronic address: mmahmoud@ump.edu.pl.
Mahmoud Diaa HindawiFaculty of Medicine, Al-Azhar University, Cairo, Egypt; Medical Research Group of Egypt, Negida Academy, Arlington, MA, USA. Electronic address: dr.md.hunt@gmail.com.
Ayman K AwadFaculty of Medicine, Ain-Shams University, Cairo, Egypt. Electronic address: ahmedkawad@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvaluate the effect of mavacamten on echocardiographic parameters and cardiac biomarkers in patients with hypertrophic cardiomyopathy (HCM).

methodsWe searched PubMed, SCOPUS, Web of Science, and Cochrane Library until November 2023. Results were reported as mean difference (MD) and Risk Ratio (RR) with 95 % confidence intervals (CI).

resultsSeven studies with 524 patients (456 with obstructive HCM and 59 with non-obstructive HCM) were included. Mavacamten significantly improved septal early diastolic mitral annular velocity (e') (MD 0.78, 95 % CI [0.51 to 1.05]) and left ventricular mass index (LVMI). It reduced left ventricular outflow tract (LVOT) gradient, NT-proBNP (MD -557.14, 95 % CI [-685.59 to -428.68]), and troponin levels. Improvements were also seen in left atrial volume index (MD -6.26, 95 % CI [-8.88 to -3.63]) and E/e' ratios, particularly in obstructive HCM patients.

conclusionMavacamten enhances echocardiographic and cardiac biomarker outcomes in HCM patients on short-term follow-up. Limited data on non-obstructive HCM require cautious interpretation.

Indexed as

Cardiomyopathy, HypertrophicEchocardiographyHeart VentriclesUracilVentricular Function, LeftBiomarkersHumansBiomarkersUracilBeta-blockersCardiac myosin inhibitorHypertrophic cardiomyopathyMavacamten

Identifiers

PMID40441331
PMCPMC12327524

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.